Protalix BioTherapeutics, Inc. (NYSE:PLX - Get Free Report)'s share price traded down 2.1% during mid-day trading on Thursday . The stock traded as low as $2.27 and last traded at $2.33. 368,279 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 664,999 shares. The stock had previously closed at $2.38.
Analyst Ratings Changes
Several equities analysts recently commented on the stock. HC Wainwright upped their price target on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a "buy" rating in a report on Monday, February 3rd. StockNews.com lowered Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 4th.
Check Out Our Latest Stock Analysis on Protalix BioTherapeutics
Protalix BioTherapeutics Trading Up 0.4 %
The company has a 50-day simple moving average of $2.32 and a 200 day simple moving average of $1.64. The company has a market cap of $170.83 million, a P/E ratio of -17.85 and a beta of 0.75.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in PLX. GSA Capital Partners LLP boosted its position in Protalix BioTherapeutics by 8.5% in the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company's stock valued at $444,000 after buying an additional 33,969 shares during the period. XTX Topco Ltd bought a new stake in shares of Protalix BioTherapeutics during the third quarter valued at approximately $36,000. Virtu Financial LLC purchased a new stake in shares of Protalix BioTherapeutics in the third quarter valued at approximately $44,000. Sanctuary Advisors LLC bought a new position in Protalix BioTherapeutics in the third quarter worth approximately $38,000. Finally, PFG Investments LLC purchased a new position in Protalix BioTherapeutics during the 4th quarter worth $39,000. 16.53% of the stock is currently owned by institutional investors.
About Protalix BioTherapeutics
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Featured Articles
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
